Longitudinal proteomic profiling provides insights into host response and proteome dynamics in COVID‐19 progression

In managing patients with coronavirus disease 2019 (COVID‐19), early identification of those at high risk and real‐time monitoring of disease progression to severe COVID‐19 is a major challenge. We aimed to identify potential early prognostic protein markers and to expand understanding of proteome d...

Full description

Saved in:
Bibliographic Details
Published in:PROTEOMICS 2021-06, Vol.21 (11-12), p.e2000278-n/a
Main Authors: Lee, Jee‐Soo, Han, Dohyun, Kim, So Yeon, Hong, Ki Ho, Jang, Myoung‐jin, Kim, Man Jin, Kim, Young‐gon, Park, Jae Hyeon, Cho, Sung Im, Park, Wan Beom, Lee, Kyung Bok, Shin, Ho Seob, Oh, Hyeon Sae, Kim, Taek Soo, Park, Sung Sup, Seong, Moon‐Woo
Format: Article
Language:English
Subjects:
Biological activity
Biomarkers
Coronaviruses
COVID-19
Degranulation
Immune response
Immune response (humoral)
Interferon
Keywords
Lipid metabolism
Lipids
Monitoring
prognosis
Proteins
Proteomes
proteomics
serum
Severe acute respiratory syndrome coronavirus 2
severity
Telemedicine
Viral diseases
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In managing patients with coronavirus disease 2019 (COVID‐19), early identification of those at high risk and real‐time monitoring of disease progression to severe COVID‐19 is a major challenge. We aimed to identify potential early prognostic protein markers and to expand understanding of proteome dynamics during clinical progression of the disease. We performed in‐depth proteome profiling on 137 sera, longitudinally collected from 25 patients with COVID‐19 (non‐severe patients, n = 13; patients who progressed to severe COVID‐19, n = 12). We identified 11 potential biomarkers, including the novel markers IGLV3‐19 and BNC2, as early potential prognostic indicators of severe COVID‐19. These potential biomarkers are mainly involved in biological processes associated with humoral immune response, interferon signalling, acute phase response, lipid metabolism, and platelet degranulation. We further revealed that the longitudinal changes of 40 proteins persistently increased or decreased as the disease progressed to severe COVID‐19. These 40 potential biomarkers could effectively reflect the clinical progression of the disease. Our findings provide some new insights into host response to SARS‐CoV‐2 infection, which are valuable for understanding of COVID‐19 disease progression. This study also identified potential biomarkers that could be further validated, which may support better predicting and monitoring progression to severe COVID‐19.
ISSN:1615-9853
1615-9861
DOI:10.1002/pmic.202000278